Literature DB >> 2693113

Effect of ketanserin on macrocirculatory and microcirculatory blood flow in patients with intermittent claudication. A prospective randomized study.

R C Beckers1, P J Jörning, D W Slaaf, R S Reneman, M J Jacobs.   

Abstract

The effect of ketanserin on macrocirculatory and microcirculatory blood flow was investigated in a placebo-controlled, double-blind trial in 11 patients suffering from intermittent claudication using Doppler velocimetry and intravital skin capillary microscopy, respectively. After 1 year of treatment no significant change was observed either in the ketanserin or the placebo group. It appears that ketanserin has no significant effect on macrocirculatory blood flow and microcirculatory nutritional skin blood flow in patients with intermittent claudication.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2693113     DOI： 10.1007/bf00679787

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  9 in total

1.  Evaluation and clinical application of the flying spot method in clinical nailfold capillary TV-microscopy.

Authors:  C Boss; P Schneuwly; F Mahler
Journal:  Int J Microcirc Clin Exp       Date:  1987

2.  Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist.

Authors:  G J Wenting; A J Man in 't Veld; A J Woittiez; F Boomsma; M A Schalekamp
Journal:  Br Med J (Clin Res Ed)       Date:  1982-02-20

3.  Red blood cell velocity in nailfold capillaries of man measured by a television microscopy technique.

Authors:  A Bollinger; P Butti; J P Barras; H Trachsler; W Siegenthaler
Journal:  Microvasc Res       Date:  1974-01       Impact factor: 3.514

4.  Placebo-controlled, double-blind, two-centre trial of ketanserin in intermittent claudication.

Authors:  H Bounameaux; T Holditch; H Hellemans; A Berent; R Verhaeghe
Journal:  Lancet       Date:  1985-12-07       Impact factor: 79.321

5.  Clinical, haemodynamic, rheological, and biochemical findings in 126 patients with intermittent claudication.

Authors:  J A Dormandy; E Hoare; J Colley; D E Arrowsmith; T L Dormandy
Journal:  Br Med J       Date:  1973-12-08

6.  Placebo-controlled double-blind trial of ketanserin in treatment of intermittent claudication.

Authors:  J De Cree; J Leempoels; H Geukens; H Verhaegen
Journal:  Lancet       Date:  1984-10-06       Impact factor: 79.321

7.  Placebo-controlled trial of ketanserin in the treatment of intermittent claudication.

Authors:  H A Cameron; P C Waller; L E Ramsay
Journal:  Angiology       Date:  1987-07       Impact factor: 3.619

8.  Serotonin and the flow properties of blood.

Authors:  R T Walker; A Matrai; L Bogar; J A Dormandy
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

9.  Prevention of atherosclerotic complications: controlled trial of ketanserin. Prevention of Atherosclerotic Complications with Ketanserin Trial Group.

Authors: 
Journal:  BMJ       Date:  1989-02-18
  9 in total
  1 in total

Review 1.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.